While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Dr. Daniel Benhuri, a board-certified internal medicine physician and highly rated concierge doctor in Beverly Hills, is now ...

As more CFOs step into the public spotlight by participating in events and conferences, the cost of misspeaking and the ...

Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.

Eli Lilly found itself in a pharmaceutical pickle after its CFO claimed telehealth partners don’t compound key weight-loss ...

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Business Model Mastery’s Substack. In this article, we will ...

GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make the process of switching from a compounded GLP-1 to a brand-name GLP-1 ...

But behind the headlines and hashtags lies a disturbing trend that deserves urgent attention: the rise of compounded GLP-1s ...